Medical/Pharmaceuticals
Complete Genomics integrates NVIDIA Parabricks to offer researchers faster, more cost-effective and accurate genomic sequencing analysis
Complete Genomics DNBSEQ data and NVIDIA Parabricks yield deeper insights into genetic variants with deep learning SAN JOSE, Calif., Oct. 29, 2024 /PRNewswire/ -- Complete Genomics today announced an integration of its next-generation sequencing (NGS) DNBSEQ platforms* with NVIDIA Parabricks sof...
2024-10-29 21:00
1928
Qilian International Holding Group Limited Announces Name Change to BGM Group Ltd.
CHENGDU, China, Oct. 29, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: BGM) is pleased to announce that effective onOctober 30, 2024, the Company will change its name to "BGM Group Ltd." In connection with the name change, the trading symbol of ...
2024-10-29 20:00
3550
GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies
YONGIN, South Korea, Oct. 28, 2024 /PRNewswire/ -- GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy (GA...
2024-10-29 09:13
3044
KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I
Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024 SAN FRANCISCO, Oct. 28, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to...
2024-10-29 05:42
2266
Alimetry revolutionises gut health diagnosis by integrating AI into its wearable device, raises US $18m to fuel next phase of growth
MINNEAPOLIS, Oct. 28, 2024 /PRNewswire/ -- Alimetry
2024-10-29 05:08
2546
$3M GRANT TO ACCELERATE DEVELOPMENT OF NEUROPLASTOGENS FOR SUBSTANCE USE DISORDER TREATMENT
CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY
TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION
BOULDER, Colo. , Oct. 28, 2024 /PRNewswire/ -- Tessara Therapeutics
2024-10-29 02:00
2917
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
* Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year * Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-over-Year * Net Profit Attributable to the Owners o...
2024-10-28 19:03
3484
I-Mab to Participate at the Truist Securities BioPharma Symposium
ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meet...
2024-10-28 19:00
1985
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expressio...
2024-10-28 17:00
2623
RiboX Therapeutics Announces FDA Clearance for IND Application of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has cleared its IND application for th...
2024-10-26 01:24
5321
KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)
SAN FRANCISCO, Oct. 25, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Fo...
2024-10-26 00:33
2838
WOORIEN launches 'MyVet CT Plus': Advanced Veterinary imaging Solution
* Lowering CT barriers and improving diagnostic quality * Spiral-Linear Technology with Enhanced Power * Various and Wide FOV with Reduced Scan Time HWASEONG, South Korea, Oct. 25, 2024 /PRNewswire/ -- WOORIEN Co., Ltd, a company specializing in veterinary imaging equipment and solutions, pr...
2024-10-25 21:00
4777
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 inAustralia, a self-developed oral antibacterial agent in development for the treatment of nontuberculous mycoba...
2024-10-25 19:29
3844
TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability
NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with edaravone ...
2024-10-25 15:14
3978
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
* Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing overUS$100B per year * Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics * Promising efficacy ...
2024-10-24 20:00
2216
SeekIn Presents Cost-Effective Two-Step Multi-Cancer Screening Strategy and Breakthrough Lung Cancer Early Detection Test at Early Detection of Cancer Conference in San Francisco
SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced today its innovative two-step multi-cancer screening strategy at the Early Detection of Cancer Conference in San Francisco. This approach is designed to signifi...
2024-10-24 20:00
1683
Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights
PISCATAWAY, N.J., Oct. 24, 2024 /PRNewswire/ -- Cell therapy, gene therapy, and mRNA vaccines are revolutionizing healthcare, offering innovative treatments for a wide range of diseases. However, as these therapies progress, they encounter challenges like safety assessments, cost control, and te...
2024-10-24 17:53
2051
J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy
SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ -- J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the Phase 1/2 clinical trial of its novel 4th-generation EGFR Tyrosine Kinase Inhibitor (TKI), JIN-A02, aimed at EGFR-mutated non-small cell lung cance...
2024-10-24 12:42
2351
J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance
SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- J INTS BIO, a leader in oncology drug development, has revealed interim preclinical results of its second-generation synthetic HSP90 inhibitor, JIN-001, at the ENA (EORTC-NCI-AACR) Symposium held inBarcelona, Spain, from October 23-25, 2024. The ...
2024-10-24 10:45
2270
Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance
* Two new studies show Lunit INSIGHT MMG cuts radiologist workload by 50% in a double reading environment while maintaining or improving screening quality, and predicts cancer risk up to six years in advance SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- Amid rising demands and a global shor...
2024-10-23 21:00
3616
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45
AKSADRON Releases Impact Report 2025, Showcasing the Growth of Malaysia's Drone Sports Talent Ecosystem
[Picked up by 255 media titles]
2026-09-14 15:36
Qunabox Group Opens '99 Quna Festival,' Debuting Consumer-Facing Physical AI Entertainment
[Picked up by 251 media titles]
2026-09-09 11:01Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
10276
